Shanghai Pharmaceuticals Holding (02607): The injectable cefoperazone sodium produced by Shang Yao Xinya has passed the generic drug consistency evaluation.

Shanghai Pharmaceuticals Holding (02607) announced that recently, its subsidiary Shanghai Shang Yao Xin Ya Pharmaceutical Co., Ltd. (hereinafter referred to as "Shang Yao Xin Ya") received the "Drug Supplementary Application Approval Notice" (Notice No.: 2026B01286, 2026B01287) issued by the National Medical Products Administration for the injection of ceftriaxone sodium. The drug passed the evaluation of generic drug quality and efficacy consistency. Ceftriaxone sodium for injection is used to treat respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and perioperative prophylactic infections caused by sensitive bacteria. In July 2024, Shang Yao Xin Ya applied for the evaluation of generic drug consistency for this drug to the National Medical Products Administration and it was accepted. As of the date of this announcement, the company has invested approximately RMB 3.3241 million in research and development expenses for this drug. According to relevant national policies, varieties that pass consistency evaluation will receive greater support in areas such as medical insurance payment and medical institution procurement. Therefore, the approval of ceftriaxone sodium for injection by Shang Yao Xin Ya through the evaluation of generic drug consistency is beneficial for expanding the market share of this drug, enhancing market competitiveness, and accumulating valuable experience for the company's future products in conducting consistency evaluation work.